Biosimilar Contract Manufacturing Market Size & Growth Forecast 2027–2036, By Segments (Source, Service, Therapeutic Area), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Source Segment Analysis: Mammalian (Largest Segment) vs Non-mammalian (Fastest-Growing Segment)

The mammalian source segment accounted for a 59.74% market share in the biosimilar contract manufacturing market in 2026, reflecting its established role in producing complex biologic medicines that require sophisticated cellular expression systems. Mammalian cells are particularly valuable for manufacturing biosimilars that depend on accurate protein folding, appropriate post-translational modifications, and glycosylation patterns that influence biological activity, stability, and therapeutic performance. Their suitability for producing complex monoclonal antibodies and other advanced biologics supports continued demand from pharmaceutical developers seeking reliable contract manufacturing capabilities. Contract manufacturing organizations with specialized mammalian cell culture platforms, validated production processes, and robust quality-control systems are well positioned to serve biosimilar developers navigating demanding regulatory requirements. Although mammalian manufacturing can involve considerable process complexity, infrastructure requirements, and production costs, its established technical capabilities and broad applicability across major therapeutic products underpin its leading position.

The non-mammalian source segment is expected to grow at a faster pace as manufacturers seek efficient, scalable, and cost-conscious approaches to biosimilar production, positioning it to capture an expanding 2026 share of the market. Microbial and other non-mammalian expression systems can offer advantages such as rapid cell growth, simplified cultivation, and efficient production of suitable recombinant proteins. These characteristics can help contract manufacturers improve production flexibility and reduce manufacturing complexity for products whose molecular structures and therapeutic requirements are compatible with such systems. Continued progress in expression technology, process optimization, and purification methods is expanding the potential applications of non-mammalian platforms. As biosimilar developers seek to improve manufacturing economics and broaden access to biologic therapies, demand for contract manufacturing services using these systems is likely to increase, particularly for products that do not require the complex post-translational modifications associated with mammalian expression.

Service Segment Analysis: Recombinant Non-glycosylated Proteins (Largest Segment) vs Recombinant Glycosylated Proteins (Fastest-Growing Segment)

The recombinant non-glycosylated proteins segment holds a leading position in the biosimilar contract manufacturing market service segmentation, maintaining a commanding market share in 2026 supported by demand for recombinant therapeutic proteins whose biological function does not depend on glycosylation. These products can offer comparatively straightforward expression and characterization requirements than complex glycosylated biologics, making them suitable for established manufacturing workflows and contract production arrangements. Contract manufacturing organizations provide capabilities spanning cell-line or strain development, upstream production, purification, analytical testing, and quality assurance to help biosimilar developers achieve consistent product quality and regulatory compliance. The established use of recombinant non-glycosylated proteins across several therapeutic applications also supports demand for specialized manufacturing services. As competition among biosimilar developers increases, reliable production, process consistency, cost control, and efficient technology transfer remain important considerations, reinforcing the role of contract manufacturers serving this segment.

The recombinant glycosylated proteins segment is projected to expand more rapidly in 2026 as demand grows for biosimilars targeting complex biologic medicines whose therapeutic properties are influenced by glycosylation to increase its market share. Manufacturing these proteins requires close control over cell culture conditions, glycan profiles, purification processes, and analytical characterization to demonstrate product quality and comparability with reference biologics. These technical requirements create opportunities for contract manufacturing organizations with advanced mammalian expression platforms, sophisticated analytical capabilities, and extensive biologics development expertise. Growth in biosimilar development across therapeutic categories that rely on monoclonal antibodies and other glycosylated proteins is likely to increase the need for specialized contract services. As developers seek to manage technical risks, shorten development timelines, and meet stringent regulatory expectations, experienced manufacturing partners can provide valuable infrastructure and process knowledge. Improvements in process monitoring, glycosylation control, and analytical technologies are expected to further support the expansion of this service segment.

Therapeutic Area Segment Analysis: Rheumatoid Arthritis (Largest Segment) vs Oncology (Fastest-Growing Segment)

The rheumatoid arthritis segment represents the largest therapeutic area in the biosimilar contract manufacturing market, holding a dominant market share in 2026 supported by the established use of biologic therapies to manage chronic inflammatory and autoimmune conditions. Biologic medicines targeting specific immune pathways have become important treatment options for patients whose disease activity requires more advanced intervention, creating opportunities for biosimilars to improve treatment affordability and broaden access. Contract manufacturing organizations support the development and commercial supply of these products through specialized biologics production, purification, analytical testing, and quality-control services. Because biosimilars must demonstrate high similarity to their reference products, manufacturers need robust process controls and analytical methods to maintain consistency and satisfy regulatory expectations. Continued interest in reducing treatment costs, expanding patient access, and supporting the sustainable supply of biologic therapies underpins demand for contract manufacturing services associated with rheumatoid arthritis treatments.

The oncology segment is expected to grow at a faster pace as biosimilar adoption expands across cancer treatment and supportive care, capturing a larger share of the biosimilar contract manufacturing market in 2026. Biologic medicines play an important role in oncology, including therapies that target specific tumor pathways and treatments used to support patients during cancer care. As patents expire and additional biosimilar opportunities emerge, developers are increasingly seeking contract manufacturing partners capable of producing complex biologics at commercial scale while maintaining stringent quality standards. Oncology-related biosimilars can involve demanding development, characterization, and manufacturing requirements, making access to experienced production teams and specialized facilities particularly valuable. The need for dependable supply, cost-efficient production, and broader availability of biologic cancer treatments is likely to encourage investment in contract manufacturing capacity. Advances in manufacturing process control, analytical comparability, and regulatory expertise may further support this segment as healthcare systems seek to balance access to innovative treatments with affordability and long-term supply reliability.